07/08/2024
New Publication Alert! 🔬
We're excited to announce the publication of a new study in the prestigious Journal of Hepatology, which our clinical trial center was proud to be a part of.
The study, titled "Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", evaluated the efficacy and safety of a dual-immunotherapy for unresectable hepatocellular carcinoma (uHCC) patients.
Our team played a key role in recruiting participants, monitoring patients, and collecting high-quality data that contributed to the success of this important research. We're thrilled to see these findings published, as they have the potential to transform care and improve quality of life for those affected by uHCC.
You can access the full study here: https://www.sciencedirect.com/science/article/pii/S0168827824024243
We're grateful to all the participants, researchers, and clinicians who made this work possible. Advancing medical knowledge through rigorous clinical trials is at the heart of our mission, and we look forward to many more impactful publications to come.
Let us know if you have any questions!
